Clinical trial · Observational
Sentinel Lymph Node Biopsy in Porocarcinoma
Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Eccrine porocarcinoma (EPC) is a slow-growing carcinoma arising from the eccrine sweat glands. Based on its clinical presentation it can be confused with malignant and benign skin lesions, both. Histological examination is essential to formulate a correct diagnosis. Surgical excision with clear margins is the standard therapeutic approach while the role of sentinel lymph node biopsy (SNLB) remains controversial. The Authors report two cases of EPC of the lower limbs occurred in two women. Patients were treated by wide surgical excision of the lesion and SNLB.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Porocarcinoma | Porocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Sentinel Lymph Node | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sentinel lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients affected to porocarcinoma
- interventionNames
- Procedure: sentinel lymph node biopsy
- label
- patients affected to porocarcinoma in our centre
- interventionNames
- Procedure: sentinel lymph node biopsy
Primary outcomes (1)
- measure
- Role of SNLB in porocarcinoma in two patients evaluating the percentage of positive lymph nodes removed.
- timeFrame
- Patients were treated by wide surgical excision of the lesion and SNLB. 6 months follow-up was the time frame of the study.
- description
- The investigators evaluated the role of SNLB in patients affected to moderate and high risk porocarcinoma.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
patients affected to moderate and high risk porocarcinoma, in according to hystophatological findings, submitted to SNLB. Inclusion criteria: 1. Thickness greater than or equal to 5mm 2. mitoses per 10 high-power field greater than or equal to 7 3. Immunohistochemical (IHC) analysis positive for :carcinoembryonic antigen (CEA), cytokeratin (CK) 5,7 and epithelial membrane antigen (EMA). 4. Informed consent obtained for the SNLB procedure.
References
Publications (0)
Data not yet available